Your browser doesn't support javascript.
loading
Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients.
Nabieva, Naiba; Häberle, Lothar; Brucker, Sara Y; Janni, Wolfgang; Volz, Bernhard; Loehberg, Christian R; Hartkopf, Andreas D; Walter, Christina-Barbara; Baake, Gerold; Fridman, Alexander; Malter, Wolfram; Wuerstlein, Rachel; Harbeck, Nadia; Hoffmann, Oliver; Kuemmel, Sherko; Martin, Bernhard; Thomssen, Christoph; Graf, Heiko; Wolf, Christopher; Lux, Michael P; Bayer, Christian M; Rauh, Claudia; Hack, Carolin C; Almstedt, Katrin; Gass, Paul; Heindl, Felix; Brodkorb, Tobias; Lindner, Christoph; Kolberg, Hans-Christian; Krabisch, Petra; Weigel, Michael; Steinfeld-Birg, Dieter; Kohls, Andreas; Brucker, Cosima; Schulz, Volker; Fischer, Gunnar; Pelzer, Volker; Rack, Brigitte; Beckmann, Matthias W; Fehm, Tanja; Rody, Achim; Maass, Nicolai; Hein, Alexander; Fasching, Peter A.
Afiliação
  • Nabieva N; Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
  • Häberle L; Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
  • Brucker SY; Biostatistics Unit, Department of Gynecology, Erlangen University Hospital, Erlangen, Germany.
  • Janni W; Department of Gynecology, University of Tübingen, Tübingen, Germany.
  • Volz B; Department of Gynecology, Ulm University Hospital, Ulm, Germany.
  • Loehberg CR; Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
  • Hartkopf AD; Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
  • Walter CB; St. Theresien Hospital, Nuremberg, Germany.
  • Baake G; Department of Gynecology, University of Tübingen, Tübingen, Germany.
  • Fridman A; Department of Gynecology, University of Tübingen, Tübingen, Germany.
  • Malter W; Oncological Medical Practice Pinneberg, Pinneberg, Germany.
  • Wuerstlein R; Breast Center, Department of Obstetrics and Gynecology, Cologne University Hospital, Cologne, Germany.
  • Harbeck N; Evangelisches Krankenhaus Kalk, Cologne, Germany.
  • Hoffmann O; Breast Center, Department of Obstetrics and Gynecology, Cologne University Hospital, Cologne, Germany.
  • Kuemmel S; Breast Center, Department of Obstetrics and Gynecology, Cologne University Hospital, Cologne, Germany.
  • Martin B; Breast Center, Department of Gynecology and Obstetrics and CCC Munich, University of Munich (LMU), Munich, Germany.
  • Thomssen C; Breast Center, Department of Obstetrics and Gynecology, Cologne University Hospital, Cologne, Germany.
  • Graf H; Breast Center, Department of Gynecology and Obstetrics and CCC Munich, University of Munich (LMU), Munich, Germany.
  • Wolf C; Department of Gynecology, Essen University Hospital, Essen, Germany.
  • Lux MP; Breast Unit, Essen Mitte Clinics, Evangelische Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany.
  • Bayer CM; Tuttlingen Clinic, Tuttlingen, Germany.
  • Rauh C; Department of Gynecology, Martin Luther University of Halle-Wittenberg, Halle (Saale), Germany.
  • Hack CC; Helios Clinics Meiningen, Meiningen, Germany.
  • Almstedt K; Medical Center Ulm, Ulm, Germany.
  • Gass P; Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
  • Heindl F; Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
  • Brodkorb T; Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
  • Lindner C; Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
  • Kolberg HC; Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
  • Krabisch P; Department of Gynecology, Mainz University Hospital, Mainz, Germany.
  • Weigel M; Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
  • Steinfeld-Birg D; Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
  • Kohls A; Department of Gynecology, Erlangen University Hospital, Friedrich Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
  • Brucker C; Agaplesion Diakonie Clinic Hamburg, Hamburg, Germany.
  • Schulz V; Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany.
  • Fischer G; Department of Gynecology, Clinic of Chemnitz gGmbH, Chemnitz, Germany.
  • Pelzer V; Department of Gynecology, Leopoldina Hospital Schweinfurt, Schweinfurt, Germany.
  • Rack B; Gynecologic Oncologic Practice Steinfeld-Birg, Augsburg, Germany.
  • Beckmann MW; Protestant County Hospital of Ludwigsfelde-Teltow, Ludwigsfelde-Teltow, Germany.
  • Fehm T; Department of Gynecology and Obstetrics, Nuremberg General Hospital, Paracelsus Medical University, Nuremberg, Germany.
  • Rody A; Gynecologic Practice abts+partner, Kiel, Germany.
  • Maass N; Mittweida Hospital gGmbH, Mittweida, Germany.
  • Hein A; Department of Gynecology, GFO Clinics Bonn, Bonn, Germany.
  • Fasching PA; Department of Gynecology, Ulm University Hospital, Ulm, Germany.
Int J Cancer ; 145(8): 2114-2121, 2019 10 15.
Article em En | MEDLINE | ID: mdl-30901076
ABSTRACT
One of the most common adverse events (AEs) occurring during treatment with aromatase inhibitors (AIs) is musculoskeletal pain. The aim of our study was to analyze the influence of preexisting muscle/limb pain and joint pain on the development of AI-induced musculoskeletal AEs. Women eligible for upfront adjuvant endocrine therapy with letrozole were included in the PreFace study, a multicenter phase IV trial. During the first treatment year, they were asked to record musculoskeletal AEs monthly by answering questions regarding pain symptoms and rating the pain intensity on a numeric rating scale from 0 (no pain) to 10 (very strong pain). Pain values were compared using nonparametric statistical tests. Overall, 1,416 patients were evaluable. The average pain value over all time points in women with preexisting muscle/limb pain was 4.3 (median 4.3); in those without preexisting pain, it was 2.0 (median 1.7). In patients without preexisting muscle/limb pain, pain levels increased relatively strongly within the first 6 months (mean increase +0.9, p < 0.00001) in comparison with those with preexisting pain (mean increase +0.3, p < 0.001), resulting in a statistically significant difference (p < 0.00001) between the two groups. The development of joint pain was similar in the two groups. Women without preexisting muscle/limb pain or joint pain have the greatest increase in pain after the start of adjuvant AI therapy. Women with preexisting pain have significantly higher pain values. The main increase in pain values takes place during the first 6 months of treatment.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Pós-Menopausa / Dor Musculoesquelética / Letrozol Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Middle aged Idioma: En Revista: Int J Cancer Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Pós-Menopausa / Dor Musculoesquelética / Letrozol Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Middle aged Idioma: En Revista: Int J Cancer Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Alemanha